Upfront low-dose biosimilar rituximab as first biologic therapy after triple csDMARD failure in seropositive rheumatoid arthritis: a prospective real-world strategy study
Introduction Limited access to biologic disease-modifying antirheumatic drugs (bDMARDs) in resource-constrained settings influences treatment sequencing after failure of conventional synthetic DMARDs (csDMARDs). Evidence regarding upfront use of low-dose rituximab as first biolo…